Telemedicine or HealthTech Investments

Since 2022, Social Capital Group has been a strategic shareholder at healthtech and telemedicine companies covering Southeast Asia. The companies show consistent growth in revenue and consultation volume, with a focus on financial performance, regional expansion efforts in Indonesia and Vietnam, and media outreach initiatives to raise awareness of the business. Here are some key figures covering Q3 of 2023:

  1. Revenue for the three months ended September 30, FY2023: S$5.2 million, a 62% increase from the previous year.
  2. Consultation volume for the same period: over 101,000.
  3. Revenue target for the year: S$20 million.
  4. Revenue growth in Q3 FY2023: 8.2% from the previous quarter.
  5. Consultations growth in Q3 FY2023: 4.4% from the previous quarter.
  6. Revenue contribution from teleconsultations: 86.1%.
  7. Revenue for 9M FY2023: S$14.2 million, an 86% increase from the previous year.
  8. Consultations for 9M FY2023: about 279,000, a 93% increase from the previous year.
  9. Cost to income ratio for 9M FY2023: 1.24.

For more information, please visit our Singapore partners.